No differences were observed in the tumor mutational profile between those patients who achieved a best response of SD versus progression, although three of four patients with ACC-I and an additional patient with ACC-II with a MYC gene amplification all experienced PD as best response. Here, MYC is linked to adrenal cortex carcinoma.